Chronic lymphocytic leukemia is a low grade Non-Hodgkin lymphoma and the most frequent form of leukemia in western countries. The disease is characterized by a highly variable individual course. Clinical research has led to improvements in diagnostics, determination of risk profile and more effective therapy options. Chemoimmunotherapy is used as standard therapy for patients in advanced stages of the disease while the watch and wait strategy is the standard of care for patients in early stages of the disease or without clinical symptoms. Enrolment of patients in clinical trials is essential to allow further development of potential new therapies. It is anticipated that besides the clinical staging system new scores, models and methods, such as the minimal residual disease (MRD) assessment will gain importance in evaluation of the individual risk profile and treatment response.
|Translated title of the contribution||Chronic lymphocytic leukemia|
|Number of pages||5|
|Publication status||Published - Dec 2012|
- Lymphocytic leukaemia
- Minimal residual disease
- Prognostic score
- Watch and wait